TGA takes BioV8 and former directors to Federal Court over peptide advertising
28 Sep 2026
The case involves A.C.N. 641 483 703 Pty Ltd, formerly known as BioV8 Pty Ltd, and former directors Edward McGill and Nicholas Austin.
According to the TGA, BioV8 advertised prescription-only therapeutic goods, including peptides, through its website and social media between 6 June 2024 and 14 July 2025.
The products named in the allegations include BPC-157, CJC-1295 and GHRP-6.
Claims about serious health conditions
The TGA alleges that some of the advertising promoted peptides for conditions including cancer, HIV/AIDS and mental illness.
Under Australia's therapeutic goods advertising rules, certain claims about serious diseases and conditions are classified as restricted or prohibited representations. Such claims cannot be used to advertise therapeutic goods unless the required approval or permission has been granted.
The regulator also alleges that Mr McGill and Mr Austin were involved in the alleged unlawful advertising by assisting, encouraging or arranging the conduct.
The TGA is seeking court declarations and financial penalties against the company and the two former directors.
Because the former BioV8 company is currently in liquidation, the case against the company requires permission from the Federal Court to proceed.
TGA increases focus on peptide products
The TGA said many peptide products imported or supplied in Australia are unapproved therapeutic goods. These products are not included in the Australian Register of Therapeutic Goods (ARTG) and have not been assessed by the regulator for safety, quality or effectiveness.
Professor Anthony Lawler, Deputy Secretary of the Department of Health, Disability and Ageing and head of the TGA, said businesses and individuals involved in unlawful peptide advertising could face regulatory action.
The TGA has also added unapproved peptide products to its priority compliance areas for 2026–27. The move follows increased detection of concerns involving the importation, supply and advertising of these products.
The court proceedings are ongoing, and the TGA said it will not provide further comment while the matter is before the Court.
TGA takes BioV8 and former directors to Federal Court over peptide advertising
Source: Therapeutic Goods Administration (TGA)